HepaRegeniX achieves further milestone related to proof of safety and efficacy for MKK4 inhibition in an advanced chronic liver disease model

New preclinical data indicate beneficial therapeutic effects in non-alcoholic steatohepatitis (NASH)-associated liver carcinomas.